PET/CT scan test for neuroendocrine tumors with a special tracer
Part of Cancer clinical trials.
This study uses a PET/CT scan with a small amount of radioactive tracer to see how neuroendocrine tumors are behaving in adults. It may help doctors better detect and evaluate these tumors, especially when symptoms suggest a carcinoid-type hormone problem.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older.
- If you can become pregnant, you must not be within the last 10 days of your last menstrual period and you will need a negative pregnancy test.
- Be able and willing to follow study instructions and attend required visits.
- Have symptoms suggestive of a neuroendocrine tumor or carcinoid-type hormone symptoms, or have a biopsy-proven neuroendocrine tumor.
- If you are pregnant or currently nursing, you cannot join.
- Do not have had surgery in the area being scanned within the last 2 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two types of PET scans to see which one better detects neuroendocrine tumors (rare cancers that grow slowly in the body). You'll receive both scans to help doctors understand which imaging method works best.
This early-phase study tests whether a special scan using 68Ga-HA-DOTATATE can help identify or diagnose tumors that have “somatostatin receptors.” It also checks how safe this scanning approach is and whether it provides useful information for people who may have these tumor types.
This trial tests a special PET scan to better evaluate gastroenteropancreatic neuroendocrine tumors (GEP-NETs). It may help your doctor see where the tumors are in your body.
This study tests an imaging scan using a special tracer (68Ga-HA-DOTATATE) to look for tumors that have somatostatin receptors. It may help doctors better locate suspected tumor sites so treatment planning can be more accurate.
This trial looks at how useful a specific scan (68Ga-DOTA-TATE PET/CT) is for tumors that have certain “targets” (somatostatin receptors). It may help doctors better identify and guide care for neuroendocrine tumors.
This trial tests a new type of PET scan using a radioactive tracer called 61Cu-NODAGA-LM3 to detect neuroendocrine tumors (NETs). The goal is to see if it works as well as or better than the standard scan. If you have a NET and need a scan for staging or treatment planning, you might be able to join.
Hear when a new Neuroendocrine Tumors, NET trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.